Table 1.
Baseline characteristics and clinical parameters of control, T2DM and DPN groups.
| General characteristic | Control group | T2DM group | DPN group | p* | p# | p& |
|---|---|---|---|---|---|---|
| Number of cases | 110 | 83 | 65 | |||
| Gender (Male/Female) | 47/63 | 41/42 | 30/35 | 0.357 | 0.659 | 0.695 |
| Average age (years) | 57.3±8.2 | 56.5±7.9 | 58.2±7.3 | 0.496 | 0.466 | 0.181 |
| Height (cm) | 165.4±5.5 | 164.8±6.2 | 166.7±6.7 | 0.479 | 0.166 | 0.076 |
| Weight (kg) | 64.1±7.5 | 63.6±6.6 | 63.1±5.8 | 0.630 | 0.357 | 0.631 |
| BMI (kg/m2) | 23.4±2.5 | 23.5±3.2 | 22.8±2.7 | 0.808 | 0.138 | 0.159 |
| Clinical parameters | ||||||
| Course of disease | 8.4±2.6 | 12.7±4.0 | / | / | <0.001 | |
| FBG (mmol/L) | 4.9±0.4 | 7.1±1.7 | 9.2±1.4 | <0.001 | <0.001 | <0.001 |
| PGL (mmol/L) | 6.8±0.7 | 12.7±2.3 | 16.1±3.1 | <0.001 | <0.001 | <0.001 |
| HbAlc | 4.2±0.5 | 7.0±0.4 | 8.7±1.5 | <0.001 | <0.001 | <0.001 |
| 2-h FCP (ng/ml) | 4.3±0.3 | 5.8±0.5 | 9.2±2.0 | <0.001 | <0.001 | <0.001 |
| FCP (ng/ml) | 1.1±0.1 | 2.1±0.2 | 5.8±1.5 | <0.001 | <0.001 | <0.001 |
| TG (mmol/L) | 1.7±0.2 | 1.7±0.3 | 1.8±0.5 | 0.999 | 0.064 | 0.134 |
| Cholestenone (mmol/L) | 4.9±0.7 | 4.7±0.8 | 4.8±0.5 | 0.066 | 0.314 | 0.379 |
| HDL (mmol/L) | 1.4±0.5 | 1.3±0.2 | 1.3±0.4 | 0.087 | 0.172 | 0.999 |
| LDL (mmol/L) | 2.4±0.3 | 2.4±0.4 | 2.5±0.4 | 0.999 | 0.062 | 0.133 |
| 24 h UME (mg/d)*# | 8.2±1.1 | 73.3±9.6 | 120.8±14.3 | <0.001 | <0.001 | <0.001 |
T2DM – type 2 diabetes mellitus; DPN – diabetic peripheral neuropathy; FBG – fasting blood glucose; PGL – postprandial glucose level; HbAlc – glycosylated hemoglobin; 2-h FCP – 2 h fasting C-peptide; FCP – fasting C-peptide; TG – triglycerides; HDL – high-density lipoprotein; LDL – dow-density lipoprotein; UME – urinary microalbumin excretion; BMI – body mass index;
*
p<0.05, control group vs. T2DM group;
#
control group vs. DPN group;
&
T2DM group vs. DPN group.
The independent samples t-test was used to analyze data.